Showing the latest 10 filings. Sign in to filter or browse the full history. View full history
Showing 10 of 72 filings.
29 Sept 2026 1 filing
ESG rating update
ESG rating update: Crisil assigns Aether Industries a rating of 58, up from 51.
Rating dated September 28, 2026.
The company did not engage Crisil; rating conducted independently from public information.
Category: Adequate.
Result may influence ESG perception; no direct financial impact disclosed.
16 Sept 2026 1 filing
Meeting Details
Date: September 23, 2026; One-on-One meetings; Physical in Mumbai; Investors: Multiple Institutional Investors.
Participants
Key company participant: Company Secretary & Compliance Officer.
Purpose
Purpose: Schedule investor meetings; no UPSI to be discussed.
12 Sept 2026 1 filing
AGM details
Date: 11 September 2026
Time: 11:00 AM
Mode: Video Conferencing / Other Audio-Visual Means
Key resolutions
Adoption of standalone and consolidated financial statements and reports.
Dividend declaration approved.
Remuneration of Cost Auditor for FY 2026-27 approved.
Re-appointment of multiple directors (non-executive and whole-time).
Voting results
All resolutions passed as per Scrutinizer's report.
Dividend
Dividend declaration approved; per-share amount not disclosed.
Director changes
Re-appointments of directors, including non-executive and whole-time roles, approved.
Auditor appointments
Remuneration for Cost Auditor approved for FY 2026-27.
11 Sept 2026 1 filing
AGM details & resolutions
AGM held on Sep 11, 2026 at 11:00 IST via VC / OAVM.
Resolution 1: Adopt standalone and consolidated financial statements for the year ended Mar 31, 2026.
Resolution 2: Re-appoint Kamalvijay Ramchandra Tulsian as Non-Executive Director.
Resolution 3: Re-appoint Ishita Surendra Manjrekar as Non-Executive Director.
Resolution 4: Ratify remuneration payable to Cost Auditor for FY 2026-27.
Resolution 5: Re-appoint Ashwin Jayantilal Desai as Managing Director.
Resolution 6: Re-appoint Purnima Ashwin Desai as Whole-time Director.
Resolution 7: Re-appoint Rohan Ashwin Desai as Whole-time Director.
Resolution 8: Re-appoint Aman Ashwinbhai Desai as Whole-time Director.
19 Aug 2026 3 filings
Overview
Specialty chemical manufacturer based in India; standalone BRSR for FY2025-26.
Turnover ₹9,401.69 million; three operating sites; 16 states; 20 international countries.
Key ESG Risks & Opportunities
Transition risk from fossil-fuel utilities; mitigated by 31 MW solar.
Water-intensive processes require ZLD and SBT; aims to reduce effluent and cost.
Data privacy/cybersecurity risk; mitigated by ISO 27001 and SRP solvent recovery.
CO2 reduction opportunity via Converge; capture up to 40% CO2 by weight.
On-site solar and SRP deployment support lower energy/material costs.
Governance & Policy Highlights
Board-approved ESG policies cover nine NGRBC principles; no separate sustainability committee.
Executive Directors oversee sustainability decisions; governance described in BRSR; independent assurance obtained.
Whistleblower policy and POSH; no penalties; one shareholder complaint.
Independent assurance by JointValues on BRSR Core; standalone boundary.
RPT disclosures: 2.97% purchases, 90.99% loans, 100% investments with related parties.
Value chain supplier code; 75% value chain partners covered by awareness.
Social Responsibility & Workforce
Total workforce 1,449; 817 permanent, 632 workers; 96.33% male, 3.67% female among permanent.
Well-being spend 0.34% of revenue; LTIFR 0; injuries 4 employees, 12 workers.
Return-to-work/retention rate 100% for parental leave.
CSR beneficiaries ~2,000; education, healthcare, elderly care, inequality reduction.
100% training for permanent employees and workers.
No unions; grievance mechanisms include WB/POSH; accessible to differently abled.
Inputs: 91.28% sourced within India; 1.54% directly from MSMEs.
Environmental Performance
Total energy consumption 472.74 TJ; renewable 92.98 TJ; non-renewable 84.82 TJ; fuel 149.73 TJ.
Energy intensity 0.50 per turnover; 0.32 per physical output.
Water withdrawal 34,111 KL; water intensity 73.80 per PPP; 23.54 KL/FTE.
Zero Liquid Discharge implemented; SRP solvent recovery; 31 MW solar; no groundwater.
Scope 1 emissions 7,696.08 tCO2e; Scope 2 emissions 17,768.27 tCO2e.
Emission intensity: 55.10 tCO2e per million turnover; 17.58 tCO2e per FTE.
Total waste 4,399.25 MT; plastic 85.64 MT; E-waste 0.99 MT; hazardous waste 4,307.45 MT.
Recovered waste via recycling 1,126.36 MT; disposal per category described.
EcoVadis Silver; UN Global Compact member; CRISIL ESG rating; NSE sustainability rating.
Converge platform reduces CO2; target 850 KTA market.
Stakeholder Engagement & Complaints
Key stakeholder groups include customers, investors, employees, communities; multi-channel engagement; frequent interactions.
CSR Committee oversees ESG topics; stakeholder feedback reported periodically.
Shareholders filed 1 complaint; other groups had none; no unresolved grievances.
Grievance mechanisms include whistle-blower, POSH channels; accessible to all.
Approximately 30% of value chain partners assessed for human rights risks.
Other Notable Metrics
Assurance: BRSR Core independently assured by JointValues; standalone scope.
External recognitions: EcoVadis Silver; UN Global Compact member; CRISIL ESG 51; NSE 61/100.
Inputs: 91.28% sourced within India; 1.54% from MSMEs; no preferential procurement policy.
No major adverse environmental impacts reported in the value chain.
AGM details
AGM date/time 11 Sep 2026, 11:00 IST, via VC/OAVM.
Voting eligibility cut-off 5 Sep 2026.
Remote e-voting window 8–10 Sep 2026 (09:00–17:00 IST).
Key resolutions
A: Ordinary: Adopt standalone and consolidated financial statements for the year ended 31 March 2026.
B: Ordinary: Re-appoint Kamalvijay Tulsian as Non-Executive Director.
C: Ordinary: Re-appoint Ishita Surendra Manjrekar as Non-Executive Director.
D: Special: Ratify cost auditor remuneration for FY 2026-27 at ₹1,20,000.
E: Ordinary: Re-appoint Ashwin Desai as Managing Director for 5 years; monthly remuneration Rs 12.07 lakh.
F: Ordinary: Re-appoint Purnima Desai as Whole-Time Director for 5 years; Rs 12.07 lakh.
G: Ordinary: Re-appoint Rohan Desai as Whole-Time Director for 5 years; Rs 16.61 lakh.
H: Ordinary: Re-appoint Aman Desai as Whole-Time Director for 5 years; Rs 18.11 lakh.
Voting results
Voting results not disclosed in this filing.
Director changes
Ordinary: Re-appoint MD/WDs: Ashwin Desai, Purnima Desai, Rohan Desai, Aman Desai for five-year terms.
Auditor appointments
Ratification of cost auditor remuneration for FY2026-27: ₹1.20 lakh.
Financial snapshot
Consolidated revenue FY2026: ₹11,601.41 MM; YoY growth 38%.
EBITDA ₹3,546.60 MM; margin 30.57%.
PAT ₹2,194.63 MM; margin 18.58%.
ROCE 9.97%; debt-equity 0.18x; net debt ₹7,398.75 MM.
Operating cash flow ₹1,423.82 MM; capex ₹6,233.16 MM; FY27 capex guide ₹3,000-3,500 MM.
Domestic revenue share 75%; exports 25%.
Site 3++ commercial production began Feb 2026; Site 5 blocks readied for Jun 2026.
19 marquee clients onboard; 50+ customer/certification audits.
Solar capacity 31 MW; ZLD and sustainability initiatives under way.
Dividend: No dividend declared in FY2025-26.
Revenue mix & drivers
CRAMS and CEM together 55% of revenue; target ~70% by FY2029-30.
LSM contributed 43% of consolidated revenue; pricing recovered in last two quarters.
Pharma & Agrochemicals: 46%; Oil & Gas: 21%; Material Science: 17%.
Milliken, Baker Hughes, SEQENS, Saudi Aramco partnerships underpin growth.
Site 3++ commenced commercial production; Site 4 ramped; Site 5 semiconductor line planned.
Pharma & Agro mix declined from 67% to 46% as new high-value segments grew.
Capex & capacity expansion
Site 3++ commenced commercial production Feb 2026; ramp-up ahead of schedule.
Site 5 (Panoli): first two production blocks for commercial June 2026; Phase 2 in progress.
Site 4 revenue rose to ₹219 crore; now ~19% of total sales.
R&D complex: 120 fume hoods and 15 labs; commissioning by FY2027-28.
FY2026 capex ~₹450-₹500 crore for Site 3++ and Site 5 Panoli; FY27 capex ₹3,000-₹3,500 crore guidance.
R&D & technology
R&D spend ₹862.13 MM (7.3% of revenue); world-class pilots and labs expanded.
R&D team ~350 scientists/engineers across 11 groups; DSIR-recognized in-house centre.
Collaborations with NCL, ICT, UTU, SVNIT; sponsored PhD programs.
Next-gen: integrated polymerisation capability; 120 fume hoods and 15 labs planned.
Digitalisation: data analytics, modelling, and process simulation to de-risk scale-up.
Geography & customers
Domestic revenue share 75%; exports to 20 countries.
Global customer base exceeds 300; 19 new marquee clients in FY2025-26.
Export markets include US, Germany, UK, Japan, and SEA; India remains strong.
Five manufacturing sites in India; Surat is the hub; Panoli site under expansion.
Growth driven by long-term CRAMS/CEM engagements and contracted manufacturing.
ESG & sustainability
31 MW solar capacity; ZLD with SRP; Converge CO2-based polyols up to 40% CO2.
EcoVadis Silver; UN Global Compact member; CRISIL ESG rating; NSE Sustainability score ~61/100.
Waste: total 4,399.25 MT; 1,126.36 MT recycled; multiple hazardous wastes managed with TSD.
Water: 34,111 KL withdrawal; 73.80 KL/₹1M PPP; renewable energy reduces footprint.
Safety: ISO 45001; 50 customer/cert audits; strong QEHS governance.
Governance & controls
Board: 12 members; 4 Executives, 6 Independent; no BoD changes in FY2025-26.
Audit Committee held 4 meetings; Risk Management Committee held 2 meetings.
Whistleblower policy in place; 2 familiarisation programs for Independent Directors.
ESOS 2021 program: total options 4.77 million; ongoing vesting and valuation under Black-Scholes.
Internal controls: robust IFCS; ongoing governance enhancements; no material audit qualifications.
Outlook & strategic priorities
Focus on CRAMS and CEM to reach ~70% of revenue by FY2029-30.
EBITDA margin target: 29-30% for FY2026-27; ROE ~9% and ROCE ~10%.
Continue Site 5 ramp, Site 3++ scale-up, and R&D expansion to 120 labs.
Leverage China+1 shift; expand in Japan, Korea, Taiwan; deepen European leadership.
Strengthen HSE, ESG governance; scale renewable energy to cut costs.
Post-year events & notable incidents
March 11, 2026: fire at external Hojiwala warehouse; ₹70.0m inventory loss.
November 29, 2023 fire: asset loss ₹299.68m; insurance receipt ₹210m; FLOP claim ₹258.23m.
Insurance recoveries and ongoing claims disclosed; no material impact on going concern.
Dividend & shareholder matters
No dividend declared for FY2025-26; dividend policy remains in place.
AGM communications moved to electronic; remote e-voting available; VC/OAVM option for meeting.
11 Aug 2026 1 filing
No brief for this announcement. This type of announcement aren’t summarised. View the original using the link below
10 Aug 2026 1 filing
Meeting Details
Dates: August 17-18, 2026
Meeting type: One-on-One / Group
Mode: Physical
Event Organizer: Ambit-Daiwa India Access
Participants
Key company executives not specified
Purpose
Intimation of participation in investor conference
No UPSI to be discussed during the Meet
Additional Notes
Schedule subject to change by the Organiser or the Company
7 Aug 2026 1 filing
Financial Performance
Q1 FY27 revenue up 27% YoY to INR3,266 million.
EBITDA INR1,028 million; margin 31% vs 30% YoY.
PAT INR627 million; PAT margin 19%.
Insurance claim for fixed assets fire received in Q1 FY27.
Capex for Q1 FY27 at INR943 million; FY27 guidance INR3,000-3,500 million.
Capacity utilization: Site2 74%, Site3 69%, Site4 59%.
Operations and Strategy
CEM and CRAMS to contribute 70%+ of revenue in next 2 years; margins rise with mix.
Onboarded 10 marquee clients; 9 audits cleared.
Phase 1 Magnum Site5 online; Phase 2 planned FY2030.
Site 3++ ramping; Milliken supply agreement; high contribution earlier than planned.
Dow collaboration: exclusive, multi-year silicone research; Surat pilot plant; potential manufacturing framework.
Capex and Capacity Expansion
Magnum Phase 1 capex INR2,200-2,300 crores; Phase 2 FY2030.
Total Magnum blocks: 16; asset turn 1.5-1.75 when Phase 1 online.
R&D expansion: 400 megahertz NMR; 15 labs; 160 fume hoods; commissioning FY2028.
Dow Collaboration and Semiconductors
Dow exclusive silicones research program; platform technology; India market opportunities.
Pilot plant in Surat; framework for long-term partnership; first stage research and pilot work.
Q&A Highlights
Order book not broken out; pursuing few high-value molecules; updates as contracts finalize.
Magnum LSM products started commercial sales; expected Q2 FY27 contribution; price $30-40/kg.
LSM volume down 22% YoY due to shift to CEM; LSM demand remains.
Oil & Gas revenue ~INR1,000 million; Baker Hughes main driver; Site4 ~INR70 crores.
Consolidated EBITDA margins guidance for CEM 28-30%.
Risks and Outlook
Execution risk in rapid expansions; safety remains top priority.